利托那韦增强阿扎那韦每日两次给药与利福平联用的药代动力学和安全性
在乌干达接受阿扎那韦/利托那韦方案治疗的HIV感染者中开展剂量递增试验,评估每日两次阿扎那韦/利托那韦能否安全克服利福平的药物相互作用。结果显示每日两次给药可使阿扎那韦谷浓度和暴露量维持在目标以上,耐受性良好。
要点
- 利福平使阿扎那韦谷浓度降低96%、AUC降低85%。
- 改为每日两次后谷浓度仅低18%、AUC24高8%。
- 每日两次给药期间谷浓度均高于蛋白调整IC90。
核心结论
- 利福平联用期间每日两次阿扎那韦/利托那韦耐受性良好,血药浓度达到目标以上。
研究设计与样本
- DERIVE(NCT04121195,EDCTP)是在乌干达接受阿扎那韦/利托那韦为基础抗逆转录病毒治疗的HIV感染者中开展的剂量递增试验,共纳入26例参与者(23例女性),中位(范围)年龄44(28-61)岁、体重67(50-75)kg,进行4次密集药代动力学访视,采用非房室分析解读数据。
主要发现
- 与PK1相比,PK2(联用利福平600 mg每日一次)时阿扎那韦谷浓度和AUC分别显著降低96%和85%。
- 升级为每日两次给药(PK3)后,谷浓度较PK1低18%,AUC24较PK1高8%。
- 利福平加倍剂量(PK4)时暴露量维持可比。
- PK1、PK3、PK4期间最低谷浓度分别为蛋白调整IC90的12.7倍、4.8倍和8.6倍,而PK2时65%的谷浓度低于定量下限(0.03 mg/L),可能低于蛋白调整IC90。
- 无参与者出现肝酶显著升高、报告严重不良事件或发生病毒血症反弹。
关键数值与推荐
- 目标最低浓度为阿扎那韦蛋白调整IC90(PA-IC90)0.014 mg/L。
- 研究期间全程使用多替拉韦50 mg每日两次以确保参与者免于亚治疗浓度阿扎那韦暴露。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent use of rifampicin and protease inhibitors. We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin. METHODS: DERIVE (NCT04121195, EDCTP) was a dose-escalation trial in people with human immunodeficiency virus (HIV) on atazanavir/ritonavir-based antiretroviral therapy (ART) in Uganda. Four intensive pharmacokinetic (PK) visits were performed: PK1 300/100 mg OD (baseline); PK2 300/100 mg OD with rifampicin 600 mg; PK3 300/100 mg twice a day (BID) with rifampicin 600 mg OD; PK4 300/100 mg BID with rifampicin 1200 mg OD. Dolutegravir 50 mg BID throughout the study period ensured participants remained protected from subtherapeutic atazanavir concentrations. The data were interpreted with noncompartmental analysis. The target minimum concentration was atazanavir's protein-adjusted IC90 (PA-IC90), 0.014 mg/L. RESULTS: We enrolled 26 participants (23 female) with median (range) age 44 (28-61) years and weight 67 (50-75) kg. Compared with PK1, atazanavir Ctau, and AUC were significantly reduced at PK2 by 96% and 85%, respectively. The escalation to BID dosing (PK3) reduced this difference in Ctau, and AUC24 to 18% lower and 8% higher, respectively. Comparable exposures were maintained with double doses of rifampicin. Lowest Ctau during PK1, PK3, and PK4 were 12.7-, 4.8-, and 8.6-fold higher than PA-IC90, respectively, whereas 65% of PK2 Ctau were below the limit of quantification (0.03 mg/L), hence likely below PA-IC90. No participant developed significant elevation of liver enzymes, reported a serious adverse event (SAE) or experienced rebound viraemia. CONCLUSIONS: Twice daily atazanavir/ritonavir during rifampicin co-administration was well tolerated and achieved plasma concentrations above the target. CLINICAL TRIALS REGISTRATION: NCT04121195. Registered on 09 October 2019, https://clinicaltrials.gov/ct2/show/NCT04121195.
引用
- Gausi K, Mugerwa H, Siccardi M, et al. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin. Clin Infect Dis. 2024. PMID: 37982585. doi:10.1093/cid/ciad700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。